All In Biotech

Drug Trial Radar · NCT05480592

A Study of HS-10380 in Chinese Participants

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HS-10380 in Chinese Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Mar 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

76

Planned (sponsor's estimate)

Start

Aug 1, 2022

Primary completion

Jun 30, 2023

Study completion Jul 30, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10380 in Chinese healthy subjects.

Conditions

  • Schizophrenia

Interventions

  • HS-10380Drug

    Administered orally as a tablet

  • PlaceboDrug

    Administered orally as a tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Experiencing Adverse Events (AEs)Time frame: Baseline to end of follow-up (a maximum of 20 days)
  2. Changes from baseline in laboratory testsTime frame: Baseline to end of follow-up (a maximum of 20 days)
  3. Changes from baseline in vital signsTime frame: Baseline to end of follow-up (a maximum of 20 days)
  4. Change from baseline in Electrocardiogram (ECG)Time frame: Baseline to end of follow-up (a maximum of 20 days)
  5. Change from baseline in weight (kg)Time frame: Baseline to end of follow-up (a maximum of 20 days)
  6. Change from baseline in physical examinationTime frame: Baseline to end of follow-up (a maximum of 20 days)
  7. Change from baseline in Simpson-Angus Scale (SAS) scoreTime frame: Baseline to end of follow-up (a maximum of 20 days)
  8. Change from baseline in Abnormal Involuntary Movement Scale (AIMS) scoreTime frame: Baseline to end of follow-up (a maximum of 20 days)
  9. Change from baseline in Barnes Akathisia Rating Scale (BARS) scoreTime frame: Baseline to end of follow-up (a maximum of 20 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.